Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
6
×
clinical trials
life sciences
national blog main
alnylam pharmaceuticals
boston
boston top stories
rna interference
fda
biotech
drugs
patisiran
alexion pharmaceuticals
aminolevulinic acid
deals
givosiran
hereditary transthyretin amyloidosis
national top stories
new york blog main
new york top stories
onpattro
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
amyotrophic lateral sclerosis (als)
andrew fire
autoimmune disorders
boehringer ingelheim
complement system
craig mello
dicerna pharamceuticals
evercore isi
evolocumab
generalized myasthenia gravis
heart attack
hepatitis b
What
drug
6
×
pharmaceuticals
6
×
alnylam
medicine
medicines
rna
rnai
data
disease
fda
interference
new
ok
pharma
second
seek
speedy
afternoon
ago
alnylam’s
alternative
approval
approved
autoimmune
based
candidate
caught
causing
cholesterol
cleared
deal
dicerna
evidence
expensive
eye
far
gene
gets
heart
hepatitis
Language
unset
Current search:
pharmaceuticals
×
drug
×
" boston blog main "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug